FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

Item
http://www.wikidata.org/entity/Q33425207
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.Ibrutinib-induced severe liver injury.Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activationThe Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
P2860

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

Item
http://www.wikidata.org/entity/Q33425207
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@ast
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@en
type
label
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@ast
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@en
prefLabel
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@ast
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
FDA Approval: Ibrutinib for Pa ...... Chronic Lymphocytic Leukemia.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-14-2225
P407
P433
P478
P577
P698
P921